Elevation Oncology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Elevation Oncology (Nasdaq: ELEV) announced that its CEO, Shawn M. Leland, will virtually present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Elevation Oncology (Nasdaq: ELEV) announced that its CEO, Shawn M. Leland, will virtually present at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on demand from September 13, 2021, at 7:00 a.m. ET. Elevation Oncology focuses on developing precision medicines for genomically defined cancers and aims to provide individualized treatment plans.
The company's lead candidate, seribantumab, targets tumor growth driven by NRG1 fusions and is currently in Phase 2 testing.
Details
News Market Reaction – ELEV
The recorded move for ELEV in the trading session of this news was +1.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Sept. 7, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that Shawn M. Leland, PharmD, Rph, Founder and Chief Executive Officer of Elevation Oncology, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on demand starting at 7:00 a.m. ET on Monday, September 13, 2021.
A webcast of the event will be accessible for 30 days on the Events page of the Company's Investor Relations website at https://investors.elevationoncology.com.
About Elevation Oncology, Inc.
Elevation Oncology is founded on the belief that every patient living with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We aim to make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of tumor growth. Together with our peers, we work towards a future in which each tumor's unique genomic test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our lead candidate, seribantumab, is intended to inhibit tumor growth driven by NRG1 fusions and is currently being evaluated in the Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion. Details on CRESTONE are available at www.NRG1fusion.com. For more information visit www.ElevationOncology.com.
Investor Contact
Argot Partners
Phone: +1 (716) 371-1125
Email: ir@ElevationOncology.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301369354.html
SOURCE Elevation Oncology
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.